HSD3B1在前列腺癌治疗中的研究进展

doi:10.3969/j.issn.1006-5725.2019.16.032

摘要/Abstract

摘要： HSD3B1基因是编码3β-羟基类固醇脱氢酶-1（3β-HSD1）的基因,而3β-HSD1是催化肾上腺前体类固醇转化为睾酮、双氢睾酮和雌激素的关键酶。在前列腺癌（PCa）的研究中,大量研究证明HSD3B1（1245 A > C）等位基因变异体与PCa患者的去势抵抗性密切相关,可作为激素敏感性PCa患者雄激素剥夺治疗反应差的预测标志物。而且,近年来的研究发现HSD3B1基因与甾体类CYP17A1抑制剂阿比特龙的体内代谢密切相关,有望成为帮助PCa患者选择个体化治疗的预测性生物标志物。因此,HSD3B1逐渐成为国内外PCa领域的研究热点。本文就HSD3B1在PCa中的最新研究进展进行综述。

关键词: HSD3B1基因, 前列腺癌, 雄激素剥夺治疗, 阿比特龙

Abstract: The HSD3B1 is a gene that encodes 3β-hydroxysteroid dehydrogenase-1（3β-HSD1）,which is a key enzyme that catalyzes the conversion of adrenal precursor steroids into testosterone, dihydrotestosterone and estrogen. In a large number of prostate cancer（PCa） studies showed that HSD3B1 （1245 A > C） allelic variants are closely related tocastration resistance of patients with PCa, and can be used as a predictivemarker for patients with hormone-sensitive prostate cancer who poorly respond toandrogen deprivation therapy. Moreover, recent studies found that the HSD3B1 gene is also closely associated with the metabolism of the steroidal CYP17A1 inhibitor, abiraterone, in vivo. Thus abiraterone is expected to be a predictive biomarker for patients with prostate cancer who receive individualized treatment. Therefore, HSD3B1 is gradually becoming a research hotspot in the field of prostate cancer. We here overview the recent studies ofHSD3B1 in prostate cancer.

Key words: HSD3B1, prostate cancer, androgen deprivation therapy, abiraterone

陈振杰, 黄应龙, 丁明霞. HSD3B1在前列腺癌治疗中的研究进展[J]. 实用医学杂志, 2019, 35(16): 2658-2663.

CHEN Zhenjie, HUANG Yinglong, DING Mingxia. Research progress of HSD3B1 in the treatment of prostate cancer[J]. The Journal of Practical Medicine, 2019, 35(16): 2658-2663.

参考文献 53

[1]	BRAY F, FERLAY J, SOERJOMATARAM I, et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424.
[2]	李显永, 官润云, 柯昆彬, 等. 甲基转移酶3在前列腺癌中的表达及其临床意义[J] . 实用医学杂志, 2019,35(1):75-79.
[3]	王宁, 刘硕, 杨雷, 等. 2018全球癌症统计报告解读[J]. 肿瘤综合治疗电子杂志, 2019, 5(1):87-97.
[4]	DAI C, HEEMERS H, SHARIFI N.Androgen signaling in prostate cancer[J]. Cold Spring Harb Perspect Med, 2017, 7(9): a030452.
[5]	HARRIS W P, MOSTAGHEL E A, NELSON P S, et al.Androgen deprivation therapy: Progress in understanding mechanisms of resistance and optimizing androgen depletion[J]. Nat Clin Pract Urol, 2009, 6(2):76-85.
[6]	HUANG Y, JIANG X, LIANG X, et al.Molecular and cellular mechanisms of castration resistant prostate cancer[J]. Oncol Lett, 2018, 15(5):6063-6076.
[7]	CEDER Y, BJARTELL A, CULIG Z, et al.The Molecular Evolution of Castration-resistant Prostate Cancer[J]. Eur Urol Focus, 2016, 2(5): 506-513.
[8]	SHIOTA M, NARITA S, AKAMATSU S, et al.Association of missense polymorphism in HSD3B1 with outcomes among men with prostate cancer treated with androgen-deprivation therapy or abiraterone[J]. JAMA Netw Open, 2019, 2(2): e190115.
[9]	KAOCHAR S, MITSIADES N.A novel mechanism to drive castration-resistant prostate cancer[J]. Trends Endocrinol Metab, 2018, 29(6): 366-368.
[10]	ROSS R W, OH W K, XIE W, et al.Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer[J]. J Clin Oncol, 2008,26(6):842-847.
[11]	HEARN J W D, ABUALI G, REICHARD C A, et al. HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: A retrospective, multicohort study[J]. Lancet Oncol, 2016, 17(10):1435-1444.
[12]	BAQUEDANO M S, GUERCIO G, COSTANZO M, et al.Mutation of HSD3B2 gene and fate of dehydroepiandrosterone[J]. Vitam Horm, 2018, 10(8): 75-123.
[13]	GOMEZ-SANCHEZ C E, LEWIS M, NANBA K, et al. Development of monoclonal antibodies against the human 3beta-hydroxysteroid dehydrogenase/isomerase isozymes[J]. Steroids, 2017, 127: 56-61.
[14]	NEUBAUER E, LATIF M, KRAUSE J, et al.Up regulation of the steroid hormone synthesis regulator HSD3B2 is linked to early PSA recurrence in prostate cancer[J]. Exp Mol Pathol, 2018, 105(1): 50-56.
[15]	AL ALAWI A M, NORDENSTROM A, FALHAMMAR H. Clinical perspectives in congenital adrenal hyperplasia due to 3beta-hydroxysteroid dehydrogenase type 2 deficiency[J]. Endocrine, 2019, 63(3): 407-421.
[16]	SIMARD J, MOISAN A M, MOREL Y.Congenital adrenal hyperplasia due to 3beta-hydroxysteroid dehydrogenase/Delta(5)-Delta(4) isomerase deficiency[J]. Semin Reprod Med, 2002,20(2):255-276.
[17]	GINGRAS S, SIMARD J.Induction of 3b-hydroxysteroid dehydrogenase/isomerase type 1 expression by interleukin-4 in human normal prostate epithelial cells, immortalized keratinocytes,colon,and cervix cancer cell lines[J]. Endocrinology,1999,140(10):4573-4584.
[18]	GINGRAS S, MORIGGL R, GRONER B, et al.Induction of 3betahydroxysteroid dehydrogenase/delta5-delta4 isomerase type 1 gene transcription in human breast cancer cell lines and in normal mammary epithelial cells by interleukin-4 and interleukin-13[J]. Mol Endocrinol, 1999,13(1):66-81.
[19]	PENG L, HUANG Y, JIN F, et al.Transcription enhancer factor-5 and a gata-like protein determine placental-specific expression of the type i human 3beta-hydroxysteroid dehydrogenase gene, HSD3B1 [J]. Mol Endocrinol, 2004,18(8):2049-2060.
[20]	LAI T C, LI H F, LI Y S, et al.Proximal gata-binding sites are essential for human HSD3B1 gene transcription in the placenta[J]. Sci Rep, 2017, 7(1):42-71.
[21]	HETTEL D, ZHANG A, ALYAMANI M, et al.Ar signaling in prostate cancer regulates a feed-forward mechanism of androgen synthesis by way of HSD3B1 upregulation[J]. Endocrinology, 2018,159(8):2884-2890.
[22]	ZHAO J C, FONG K W, JIN H J, et al.Foxa1 acts upstream of gata2 and ar in hormonal regulation of gene expression[J]. Oncogene, 2016,35(33):4335-4344.
[23]	CHI K N, ANNALA M, SUNDERLAND K, et al.A randomized phase II cross-over study of abiraterone + prednisone (ABI) vs enzalutamide (ENZ) for patients (pts) with metastatic, castration-resistant prostate cancer (mCRPC)[J]. J Clin Oncol, 2017,35(15):5002.
[24]	CHANG K H, LI R, KURI B, et al.A gain-of-function mutation in dht synthesis in castration-resistant prostate cancer[J]. Cell, 2013, 154(5):1074-1084.
[25]	AGARWAL N, HAHN A W, GILL D M, et al.Independent validation of effect of HSD3B1 genotype on response to androgen-deprivation therapy in prostate cancer[J]. JAMA Oncol, 2017, 3(6):856-857.
[26]	SANTOSH K S, JAMES W L, RAJESH S.Molecular basis for prostate cancer racial disparities[J]. Front Biosci, 2017, 22(1): 428-450.
[27]	GREEN S M, MOSTAGHEL E A, NELSON P S.Androgen action and metabolism in prostate cancer[J]. Mol Cell Endocrinol, 2012,360:3-13.
[28]	LOCKE J A, GUNS E S, LUBIK A A, et al.Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer[J]. Cancer Res, 2008, 68(15): 6407-6415.
[29]	DEB S, PHAM S, MING D S, et al.Characterization of precursor-dependent steroidogenesis in human prostate cancer models[J]. Cancers (Basel), 2018, 10(10):343-364.
[30]	HETTEL D,SHARIFI N.HSD3B1 status as a biomarker of androgen deprivation resistance and implications for prostate cancer[J]. Nat Rev Urol, 2018, 15(3):191-196.
[31]	MOSTAGHEL E A, ZHANG A, HERNANDEZ S, et al.Contribution of adrenal glands to intratumor androgens and growth of castration-resistant prostate cancer[J]. Clin Cancer Res, 2019,25(1):1-31.
[32]	HEARN J W D, XIE W, NAKABAYASHI M, et al. Association of HSD3B1 genotype with response to androgen-deprivation therapy for biochemical recurrence after radiotherapy for localized prostate cancer[J]. JAMA Oncol, 2018, 4(4):558-562.
[33]	WU G, HUANG S, NASTIUK K L, et al.Variant allele of HSD3B1 increases progression to castration-resistant prostate cancer[J]. Prostate, 2015, 75(7):777-782.
[34]	ALMASSI N, REICHARD C, LI J, et al.HSD3B1 and response to a nonsteroidal cyp17a1 inhibitor in castration-resistant prostate cancer[J]. JAMA Oncol, 2018, 4(4):554-557.
[35]	RYAN C J, CRAWFORD E D, SHORE N D, et al.The IMAAGEN study: effect of abiraterone acetate and prednisone on prostate specific antigen and radiographic disease progression in patients with nonmetastatic castration resistant prostate cancer[J]. J Urol, 2018,200(2):344-352.
[36]	PURSHOUSE K, PROTHEROE A S.Abiraterone acetate in combination with prednisone in the treatment of metastatic hormone-sensitive prostate cancer: clinical evidence and experience[J]. Ther Adv Urol, 2019, 11(19): 1-8.
[37]	CASTELLAN P, MARCHIONI M, CASTELLUCCI R, et al.Abiraterone acetate for early stage metastatic prostate cancer: patient selection and special considerations[J]. Ther Clin Risk Manag, 2018, 14: 2341-2347.
[38]	FEYERABEND S, SAAD F, LI T, et al.Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: a network meta-analysis[J]. Eur J Cancer, 2018,10(3): 78-87.
[39]	VALE C L, FISHER D J, WHITE I R et al. What is the optimal systemic treatment ofmen with metastatic, hormone-naive prostate cancer?A STOPCAP systematic review and network meta-analysis[J]. Ann Oncol, 2018,29(5):1249-1257.
[40]	LI T, FRANCO-VILLALOBOS C, PROSKOROVSKY I, et al.Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: Results from LATITUDE[J]. Cancer, 2019, 125(4): 626-632.
[41]	JAMES N D, DE BONO J S, SPEARS M R, et al. Abiraterone for prostate cancer not previously treated with hormone therapy[J]. N Engl J Med, 2017, 377(4):338-351.
[42]	FIZAZI K, TRAN N, FEIN L, et al.Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer[J]. N Engl J Med, 2017, 377(4):352-360.
[43]	CHI K N, PROTHEROE A, RODRíGUEZ-ANTOLíN A, et al. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (latitude): An international, randomised phase 3 trial[J]. Lancet Oncol, 2018, 19(2):194-206.
[44]	RYDZEWSKA L H M, BURDETT S, VALE C L, et al. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis[J]. Eur J Cancer, 2017, 10(84):88-101.
[45]	WALLIS C J D, KLAASSEN Z, BHINDI B, et al. Comparison of abiraterone acetate and docetaxel with androgen deprivation therapy in high-risk and metastatic hormone-naive prostate cancer: A systematic review and network meta-analysis[J]. Eur Urol, 2018, 73(6):834-844.
[46]	SYDES M R, SPEARS M R, MASON M D, et al.Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol[J]. Ann Oncol, 2018,29(5):1235-1248.
[47]	LI Z, BISHOP A C, ALYAMANI M, et al.Conversion of abiraterone to d4a drives anti-tumour activity in prostate cancer[J]. Nature, 2015, 523(7560):347-351.
[48]	LI Z, ALYAMANI M, LI J, et al.Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy[J]. Nature, 2016, 533(7604):547-551.
[49]	ALAMDAR A, TIAN M, HUANG Q, et al.Enhanced histone H3K9 tri-methylation suppresses steroidogenesis in rat testis chronically exposed to arsenic[J]. Ecotoxicol Environ Saf, 2019, 170(15):513-520.
[50]	ALYAMANI M, EMAMEKHOO H, PARK S, et al.HSD3B1(1245a > c) variant regulates dueling abiraterone metabolite effects in prostate cancer[J]. J Clin Invest, 2018, 128(8):3333-3340.
[51]	EMAMEKHOO H, ALYMANI M, PARK S, et al.HSD3B1 genotype and abiraterone metabolites in patients with prostate cancer[J]. J Clin Oncol, 2018, 36(6):325-343.
[52]	ALYAMANI M, LI Z, BERK M, et al.Steroidogenic metabolism of galeterone reveals a diversity of biochemical activities[J]. Cell Chem Biol, 2017, 24(7):825-832.
[53]	HAHN A W, GILL D M, NUSSENZVEIG R H, et al.Germline variant in HSD3B1 (1245 a > c) and response to abiraterone acetate plus prednisone in men with new-onset metastatic castration-resistant prostate cancer[J]. Clin Genitourin Cancer, 2018, 16(4):288-292.